

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
阿里健康信息技術有限公司
(Incorporated in Bermuda with limited liability)
(Stock code: 00241)

APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER

We refer to the announcement (the “**Announcement**”) of Alibaba Health Information Technology Limited (the “**Company**”) dated January 30, 2019 in relation to, among other things, the renewal of the non-exempt continuing connected transactions under the 2020 Outsourced Services Framework Agreement, the 2020 Platform Services Framework Agreement and the 2020 Advertising Services Framework Agreement. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board wishes to announce that, with the approval of the Independent Board Committee, Platinum Securities Company Limited, a corporation licensed to carry out Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), has been appointed as the independent financial adviser to advise the Independent Board Committee and the Independent Shareholders in connection with the 2020 CCT Agreements and their respective annual caps. The letter of advice from Platinum Securities Company Limited in respect of the 2020 CCT Agreements and their respective annual caps will be included in a circular (the “**Circular**”) to be despatched by the Company. As additional time is required to prepare and finalize the Circular, including but not limited to the letter from Platinum Securities Company Limited, the Company expects that the Circular will be despatched on or around March 13, 2019.

For and on behalf of the Board
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
SHEN Difan
Chief Executive Officer and Executive Director

Hong Kong, February 20, 2019

As at the date of this announcement, the Board comprises eight Directors, of whom (i) two are executive Directors, namely Mr. SHEN Difan and Mr. WANG Qiang; (ii) three are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei and Ms. ZHANG Yu; and (iii) three are independent non-executive Directors, namely Mr. YAN Xuan, Mr. LUO Tong and Mr. WONG King On, Samuel.